Dr. Reddy’s Laboratories Ltd, today announced the launch of Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05%, a therapeutic generic equivalent to Durezol (Difluprednate Ophthalmic Emulsion 0.05%) in the U.S. market, via an exchange filing.
The announcement is following the approval by the U.S. Food and Drug Administration (USFDA).
The Durezol brand and generic had U.S. sales of approximately $40 million MAT for the most recent twelve months ending in November 2022 according to IQVIA.
Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05% is available in 5 ml bottles in case packs of 24.
'China, Turkey Aided Pakistan During Operation Sindoor, Gave Live Updates': Deputy Chief Of Army Staff
DMart Operator, Avenue Supermarts, Reports 16.2% Hike In Standalone Revenue From Operations At ₹15,932.12 Crore
Reliance Industries To Consolidate Consumer Goods Brands, Prepares New Subsidiary For Retail IPO Launch
'Hands Tied, Escorted Amid Tight Security': Around 250 Bangladeshi Illegal Immigrants Deported To Dhaka Via Special Plane From Vadodara
